Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING‐Associated Vasculopathy with Onset in Infancy Refractory to <scp>JAK</scp> Inhibitor and Dazukibart Therapy
This case underscores the challenges in treating patients with SAVI and highlights the utility of IFN I scores as a theragnostic biomarker. Although high-dose JAKi and dazukibart failed to achieve sustained control of IFN I signaling, treatment with anifrolumab durably suppressed IFN scores and demonstrated promising efficacy, which allows for the investigation of the role of IFN I signaling in the disease pathogenesis of SAVI and other interferonopathies in future clinical trials.
Authors
- Oluwatobi Arisa (ORCID: https://orcid.org/0000-0001-6668-3105)
- Douglas B. Kuhns (ORCID: https://orcid.org/0000-0002-9971-0760)
- Sara Alehashemi (ORCID: https://orcid.org/0000-0002-6531-6108)
- Cody J. Peer (ORCID: https://orcid.org/0000-0001-9395-3473)
- Raphaela Goldbach‐Mansky
- Danielle Fink (ORCID: https://orcid.org/0000-0002-7502-7385)
- Adriana A. de Jesus (ORCID: https://orcid.org/0000-0001-8966-8362)
- William D. Figg (ORCID: https://orcid.org/0000-0003-2428-5613)
- Bjoern Buehring (ORCID: https://orcid.org/0000-0003-3841-624X)
- Andre Rastegar (ORCID: https://orcid.org/0000-0003-4724-9041)
- Ben Colton
- Kip Friend (ORCID: https://orcid.org/0009-0000-3277-026X)
- Sachin Gaurav
- Alexi Baumgardner
Institutions
- University of Wuppertal (DE)
- Frederick National Laboratory for Cancer Research (US)
- National Institute of Allergy and Infectious Diseases (US)
- National Cancer Institute (US)
- National Institutes of Health Clinical Center (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1002/art.43145
- Citations
- 8
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- Pfizer
- National Institutes of Health